Kidney Failure, Liver Failure
Conditions
Keywords
end-stage, liver diseases, cirrhosis, cancer, fulminant hepatic failure, metabolic hepatic diseases, congenital hepatic diseases, renal diseases
Brief summary
The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs. Unfortunately, these drugs lead to numerous side effects and fail to prevent the rejection occurring months later after the transplantation (chronic rejection). Recently, it has been shown that a particular type of cells present in the bone marrow, namely Mesenchymal Stem Cells (MSC), when injected to a patient, suppress its immune system and increase success rates of blood cells transplantation. This outcome opens doors to investigate the potential of these cells to provide a valuable tool for improving solid organ transplantation without the need of high concentration of immunosuppressive drugs. The present project aims at evaluating the safety and tolerability of MSC administration after liver or kidney transplantation.
Detailed description
The present project aims at evaluating the safety and tolerability of third party MSC administration after liver or kidney organ transplantation. Ten patients undergoing liver transplantation and 10 patients undergoing kidney transplantation will be included in the experimental arm to receive a single infusion of MSC. The outcome of each of these 2 subgroups will be compared with that of similar control patients undergoing liver or kidney transplantation but who will not receive MSC. Liver and kidney transplanted patients will receive standard immunosuppressive therapy, TAC-MMF-steroïds and TAC-MMF-steroïds plus an IL-2-R antibody respectively. Patients enrolled in the experimental arms will be infused with a single dose of 1,5-3,0 10E6 MSC/kg, 3(+/-2) days after the transplantation. Weaning of immunosuppression will be attempted from month 6 in liver transplant patients who did not present a rejection episode and show normal graft function and graft biopsy. Kidney transplant patients will continue standard immunosuppressive therapy indefinitely. Male or female (\>18 years) individuals unrelated to the recipient or the graft donor will be MSC donors. MSC donors need to fulfill generally accepted criteria for allogeneic HSC donation.
Interventions
BIOLOGICALMesenchymal Stem Cells
Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
Sponsors
University of Liege
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients between 18 and 75 years of age, who will undergo first Kidney Transplantation or whole Liver Transplantation from a cadaveric or donation after cardiac death (DCD) organ donor; * Fertile female patients must use a reliable contraception method; * Informed consent given by patient or his/next of kin if the patient is unable to give informed consent, for the complete (MSC + follow-up) or partial(no MSC + follow-up) study; * Successful liver/kidney transplantation, demonstration of organ function (improvement of INR in liver recipients and of creatinine in kidney recipients at 24-36h) and normal graft vasculature at Doppler examination.
Exclusion criteria
* Past history of malignant disease, with the exception of hepatocarcinoma within the Milan criteria for the Liver Transplantation patients; * Active uncontrolled infection; * HIV or HCV positive; * EBV-negative; * Retransplantation; * Combined transplantation; * Living related transplantation or split liver transplantation; * Autoimmune disease or expected impossibility to wean immunosuppression (Liver Transplantation) or corticosteroids (Kidney Transplantation); * Endotracheal intubation; * Postoperative cardiovascular instability, active hemorrhage, or any other serious clinical complication between transplantation and evaluation for suitability for MSC infusion; * For Kidney Transplantation: panel reactive antibodies (PRA) \>50%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Infusional toxicity | Within 24 hours of infusion | Incidence, timing and severity of any clinical complication related to MSC infusion, including pulmonary events or immune reactions. |
| Incidence of infections (bacterial, viral, fungal, parasitic) and cancers | Continuously over 2 years | * Incidence, timing and severity of any infection (bacterial, viral, fungal, parasitic) (blood hemoculture, urine culture, PCR CMV, PCR BK virus at month 1,2,3) * Incidence, timing and severity of malignant disease (Posttransplant lymphoproliferative disorder or other) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biopsy-proven (Banff classification) rejection rates | over 1 year | At months 3, 6, 9, 12. |
| Feasibility and safety of weaning or decreasing immunosuppression | continuously over 2 years | Decision points at months 3, 6, 9, 12. |
| Patient and graft survivals | Continuously over 2 years | — |
| Anti-MSC donor HLA antibodies. | over 1 year | To evaluate the potential development of anti-MSC donor HLA antibodies. |
| Recipient's immune function | over 1 year | To evaluate recipient's immune function (T cell blood populations (including T regs) by FACS, TREC quantification, Vβ repertoire diversity, pathogen-specific T cells, anti-organ donor HLA antibodies). |
| Effects of MSC on graft function | over 1 year | * Liver Transplantation: bilirubin, INR, transaminases, GGT, at day 7, months 1, 3, 6, 9, 12. * Kidney Transplanttaion: number of post transplant hemodialysis, creatinine at day 7, months 1, 3, 6, 9, 12. |
Countries
Belgium
Outcome results
None listed